Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07440797

EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD

Evaluation of the efficacy (reduction of inflammatory signs suggesting a local infection) and tolerance (emergence and nature of adverse event) of Vashe solution vs Saline solution in the treatment of venous or mixed leg ulcers presenting inflammatory signs suggesting heavy bacterial load

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Comprehensive Wound Healing Center and Hyperbarics, Northwell Health

New York, 11042, United States

Location contact

Alisha OROPALLO, Principal Investigator, MD

CONTACT

[email protected]

About this study

This study is carried out in United States of America in around 10 investigator sites. A total of 102 patients meeting the eligibility criteria will be included

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient, at least 18 years of age or older who has provided free, written, and informed consent,
  • Patient who has already worn compression therapy in the past and agrees to wear the two-layer compression system during the whole treatment period,
  • Patient presenting a venous or mixed leg ulcer predominantly of venous origin (ABPI between ≥0.8≤1.3,
  • Leg ulcer presenting at least 3 inflammatory signs (e.g pain, erythema...)
  • Target leg ulcer located at least 3 cm from the edge of another wound.

Exclusion criteria

  • Pregnant or breastfeeding patient,
  • Patient already participating in another clinical trial, except observational trial
  • Patient with epifascial arterial bypass (superficial arterial bypass)
  • Patient suffering from phlegmatia coerulea dolens, septic phlebitis, acute deep vein thrombosis (DVT), defined as the first 10 days from onset of symptoms, or any DVT for which compression is considered by the Investigator to be contraindicated.
  • Patient receiving or having received systemic antibiotics within the ten days prior to inclusion in the investigation, regardless of therapeutic class or indication,
  • Cancerous wound.

Treatment and study plan

Saline solution

Device

randomization to saline solution group for local management of venous or mixed leg ulcers

Vashe solution

Device

randomisation to Vashe solution group for local management of venous or mixed leg ulcers

Primary outcomes

  1. clinical success at week 4

    Time frame: week 4

    Clinical success at Week 4, defined as a clinical score ≤ 1.

Study contacts

Contact information is provided by the study sponsor or research team.

Clémence TUMBA, PharmD

CONTACT

[email protected]

+33 3 80 44 74 09 ext. 0033 +

Olivier TACCA, PhD

CONTACT

[email protected]

+33 3 80 44 74 22 ext. 0033+

Sponsors and collaborators

Lead sponsor

Laboratoires URGO

Industry

Registry information

Official study title

EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD: MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 27, 2026
Registry last updated
Mar 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.